Table 2.
Treatment change of secondary outcomes during 18-week treatment.
| Clinical characteristics | Liraglutide (n = 31) | Glimepiride (n = 28) | p Value |
|---|---|---|---|
| Body weight, kg | −3.5 (−6,0, −1.1) | 0.5 (−1.2, 2.1) | 0.001a |
| Waist circumference, cm | −3.1 (2.8) | −0.8 (4.4) | 0.019b |
| Mean systolic BP, mmHg | −3.0 (−13.0, 3.0) | −0.5 (−8.5, 8.0) | 0.176a |
| Mean diastolic BP, mmHg | −0.3 (8.0) | −0.9 (7.9) | 0.761b |
| HR at rest, bpm | 6.3 (9.6) | −2.3 (9.4) | 0.004b |
| HR during exercise, bpm | −1.0 (−6.0, 8.0) | −4.5 (−12.0, 1.0) | 0.150a |
| HbA1c, mmol/mol | −10.0 (−18.0, −4.0) | −5.5 (−12.5, −3.0) | 0.112a |
| Triglycerides, mmol/l | −0.2 (0.4) | −0.1 (0.8) | 0.492b |
| LDL, mmol/l | −0.1 (−0.5, 0.1) | −0.2 (−0.5, 0.1) | 0.994a |
| HDL, mmol/l | 0.1 (0.0, 0.2) | 0.0 (−0.1, 0.1) | 0.386a |
| CRP, mmol/l | 0.0 (−1.0, 0.1) | 0.0 (0.0, 0.2) | 0.351a |
| NT-proBNP, mg/l | −0.0 (−25.0, 11.0) | 0.0 (−15.5, 24.5) | 0.616a |
| Echocardiographic parameters | Liraglutide (n = 26) | Glimepiride (n = 22) | p Value |
| LVEF at rest, % | −2.1 (4.6) | −0.6 (5.9) | 0.367 |
| GLS at rest, % | 0.0 (2.4) | 0.6 (1.8) | 0.450b |
| E/e′ at rest | −0.5 (3.1) | −0.4 (2.4) | 0.867b |
Data are mean (SD) or median (Q1, Q3).
aMann–Whitney U test was used.
bStudent’s t-test was used.
BP, blood pressure; CRP, C-reactive protein; E, early diastolic peak velocity; E, early diastolic peak velocity; e′, early diastolic mitral annulus velocity; GLS, global longitudinal strain; HbA1c, hemoglobin A1c; HR, heart rate; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro b-type natriuretic peptide.